NW BIO PROVIDES UPDATE ABOUT PHASE III DCVAX®-L TRIAL FOR GBM AND "INFORMATION ARM" COMPASSIONATE USE PATIENTS This is mostly good news about the DCVax trial. This is one of my favorite trials. There are 2 major announcements:
1. The patients on the compassionate use arm of the trial seem to have done much better than expected. These patients had the vaccine made but were excluded from the trial because they had a recurrence before the trial could actually start. These patients usually die quickly but the vaccine seemed to help those.
2. They have changed the number of patients in the trial, as well as the point in time when they evaluate the trial. This may be good or bad - hard to tell. The good point is that will increase the chances that the trial shows positive results, however it is going to delay the results - maybe by a year. As the ICT-107 trial showed, when you look at the results too early, you can't see the effect the treatment has on the "tail" - the number of people who do well for a long period of time. You just see the people who did not respond to the treatment.
Copayment assistance program about to close If you need help paying for your treatments, send it the applications as soon as possible. I think it will only be open another day or 2.
